Thyrocare Technologies Limited announced its financial results for the second quarter of FY27, ending September 30, 2026. The company reported a consolidated revenue of ₹270.8 crore, marking a substantial 25.1% year-on-year growth. EBITDA increased by 24.9% to ₹89.3 crore, while Profit After Tax (PAT) before exceptional items rose by 25.7% to ₹60.2 crore, demonstrating strong operational performance.
Thyrocare Reports Strong Q2 FY27 Performance
Thyrocare Technologies Limited has announced robust financial results for the second quarter and half-year ended September 30, 2026. The company showcased significant year-on-year growth across key financial metrics, underscoring its continued momentum in the diagnostics sector.
Key Financial Highlights for Q2 FY27
During the second quarter of FY27, Thyrocare achieved a consolidated revenue of ₹270.8 crore, representing a healthy 25.1% increase compared to the same period last year. This growth was primarily driven by a 26.7% surge in the Pathology segment. The company’s Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) grew by 24.9% year-on-year to ₹89.3 crore. Profit After Tax (PAT) before exceptional items also saw a strong uptick, increasing by 25.7% to ₹60.2 crore.
Operational Achievements and Strategic Initiatives
Thyrocare processed a record 61.6 million tests in Q2 FY27, a 27.4% increase year-on-year, reinforcing its position as India’s largest diagnostic test volume processor. The Pathology business demonstrated strong traction with franchise revenue up 26.9% and partnership revenue up 27.9% year-on-year. The company also highlighted its commitment to quality, with Six Sigma standards leading to a 24% YoY reduction in complaints per million tests and an average turnaround time (ATAT) of 3.49 hours. Strategic initiatives include expansion into specialty diagnostics, with a focus on allergy and genomics, and the launch of a rapid home-testing Pregnancy Test Kit.
Exceptional Item
The results for the quarter included an exceptional item, a one-time, non-cash impairment charge of ₹45 crore related to the NHL business. This charge is associated with the definitive term sheet for the sale of the NHL business and does not impact the company’s operational performance.
Consolidated Financial Performance Snapshot
For the half-year ended September 30, 2026, consolidated revenue stood at ₹510.8 crore, a 24.7% growth over H1FY26. Reported EBITDA for the half-year was ₹166.6 crore, up 29.2%. Reported PAT before exceptions reached ₹111.5 crore, a 29.7% increase year-on-year.
Source: BSE
